Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

From Zero-Shot to Bedside: A Practical Playbook for Adapting Open-Source Large Language Models to Clinical Symptom Extraction.

Proceedings of machine learning research·2026
Same author

Higher Medical Urgency Is Associated With Greater Psychosocial Risk Tolerance in Liver Transplant Listing and Selection.

Transplantation·2026
Same author

Access to care affects electronic health record reliability and AI-driven disease prediction.

Nature health·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Blood cancer journal·2026
Same author

Large Language Model Predicts Surgeon Recommendations for Imaging and Surgery for Patients Presenting for Knee and Shoulder Complaints With 70% and 81% Accuracy Using Previsit Questionnaire Responses.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026

相关实验视频

Updated: Feb 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

使用现实世界的证据调查多发性骨髓瘤患者的CAR-T治疗准入.

Jaysón Davidson1,2, Anupama Kumar3, Ayan Patel2

  • 1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA.

Cancers
|February 27, 2026
PubMed
概括
此摘要是机器生成的。

多发性骨髓瘤 (MM) 的黑人患者接受CAR-T治疗的几率较低. 一些符合条件的患者缺乏记录的CAR-T治疗讨论,这表明护理途径的潜在差异.

关键词:
在CAR-T的资格上.在CAR-T疗法中,医疗保健中的差异.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

相关实验视频

Last Updated: Feb 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

科学领域:

  • 血液学恶性瘤 血液学恶性瘤
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 多发性骨髓瘤 (MM) 是一种严重的血液性恶性瘤,在黑人患者中发病率较高.
  • 化学抗原受体T细胞 (CAR-T) 疗法具有前景,但面临着难以获得的挑战.

研究的目的:

  • 调查MM患者接受CAR-T治疗的相关因素.
  • 检查疾病特征,治疗地点和人口统计学对CAR-T疗法的影响.

主要方法:

  • 使用电子健康记录 (2021-2025) 对12360名MM患者进行回顾性队列研究.
  • 后勤回归分析了人口统计,疾病阶段和CAR-T接收之间的关联.
  • 零射击GPT-4模型从临床笔记中评估了CAR-T讨论和资格.

主要成果:

  • 只有2.6%的MM患者接受了CAR-T治疗.
  • 与白人患者相比,黑人患者接受CAR-T治疗的几率明显较低 (OR 0.33).
  • 在符合条件的患者中,在种族群体之间观察到记录的CAR-T讨论中的差异.

结论:

  • 在MM中接受CAR-T治疗的情况因治疗地点和患者种族而异,在一个大型医疗系统内不同.
  • 在转诊,文档或护理途径的潜在差异可能会影响某些患者群体的CAR-T治疗机会.